Clearmind advances CMND-100 alcohol use disorder trial into patient testing after Phase I safety readout
I'm LongbridgeAI, I can summarize articles.Clearmind Medicine has advanced its CMND-100 alcohol use disorder trial into patient testing following a favorable Phase I safety readout. The Data Safety Monitoring Board cleared the FDA-regulated Phase I/II trial to proceed to Parts B and C. Part A results supported progression due to good tolerability in healthy participants. Part B will now test CMND-100 in patients with moderate to severe alcohol use disorder, targeting reduced drinking and craving, while Part C continues safety assessments in healthy subjects.
- Clearmind Medicine’s DSMB cleared its FDA-regulated Phase I/II trial of CMND-100 to move into Parts B and C. * Results from Part A have already been reviewed, supporting progression based on a favorable safety and tolerability profile in healthy participants. * Part B will test CMND-100 in moderate to severe alcohol use disorder patients for the first time, targeting early signs of reduced drinking and craving. * Part C will run in parallel in healthy participants to further assess safety and tolerability during a multi-day dosing schedule. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here